

KEWAUNEE SCIENTIFIC CORP /DE/

Form 10-Q

March 12, 2010

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the quarterly period ended January 31, 2010

or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _____ to _____

Commission file number 0-5286

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

Delaware
(State or other jurisdiction of
incorporation or organization)

2700 West Front Street

Statesville, North Carolina
(Address of principal executive offices)

38-0715562
(IRS Employer
Identification No.)

28677-2927
(Zip Code)

Registrant's telephone number, including area code: (704) 873-7202

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

(Do not check if a smaller

reporting company)

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No

As of March 2, 2010, the registrant had outstanding 2,572,743 shares of Common Stock.

Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2010

| | Page Number |
|--|--------------------|
| <u>PART I. FINANCIAL INFORMATION</u> | |
| Item 1. <u>Financial Statements</u> | |
| <u>Consolidated Statements of Operations – Three and Nine months ended January 31, 2010 and 2009</u> | 1 |
| <u>Consolidated Balance Sheets – January 31, 2010 and April 30, 2009</u> | 2 |
| <u>Consolidated Statements of Cash Flows – Nine months ended January 31, 2010 and 2009</u> | 3 |
| <u>Notes to Consolidated Financial Statements</u> | 4 |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 6 |
| <u>Review by Independent Registered Public Accounting Firm</u> | 9 |
| <u>Report of Independent Registered Public Accounting Firm</u> | 10 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 11 |
| Item 4. <u>Controls and Procedures</u> | 11 |
| <u>PART II. OTHER INFORMATION</u> | |
| Item 6. <u>Exhibits</u> | 12 |
| <u>SIGNATURE</u> | 13 |

Table of Contents

Part 1. Financial Information

Item 1. Financial Statements*Kewaunee Scientific Corporation*

Consolidated Statements of Operations

*(Unaudited)**(in thousands, except per share data)*

| | Three months ended January 31 | | Nine months ended January 31 | |
|---|----------------------------------|-----------|---------------------------------|-----------|
| | 2010 | 2009 | 2010 | 2009 |
| Net sales | \$ 21,814 | \$ 26,023 | \$ 75,151 | \$ 79,150 |
| Costs of products sold | 17,129 | 21,089 | 58,492 | 62,846 |
| Gross profit | 4,685 | 4,934 | 16,659 | 16,304 |
| Operating expenses | 3,663 | 3,440 | 11,605 | 10,884 |
| Operating earnings | 1,022 | 1,494 | 5,054 | 5,420 |
| Other income (expense) | | 3 | | (36) |
| Interest expense | (35) | (49) | (115) | (231) |
| Earnings before income taxes | 987 | 1,448 | 4,939 | 5,153 |
| Income tax expense | 333 | 488 | 1,673 | 1,595 |
| Net earnings | 654 | 960 | 3,266 | 3,558 |
| Less: net earnings attributable to the noncontrolling interest | 33 | 78 | 222 | 231 |
| Net earnings attributable to Kewaunee Scientific Corporation | \$ 621 | \$ 882 | \$ 3,044 | \$ 3,327 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders | | | | |
| Basic | \$ 0.24 | \$ 0.35 | \$ 1.19 | \$ 1.30 |
| Diluted | \$ 0.24 | \$ 0.35 | \$ 1.18 | \$ 1.30 |
| Weighted average number of common shares outstanding (in thousands) | | | | |
| Basic | 2,569 | 2,556 | 2,562 | 2,554 |
| Diluted | 2,581 | 2,556 | 2,570 | 2,563 |

See accompanying notes to consolidated financial statements.

Table of Contents*Kewaunee Scientific Corporation*

Consolidated Balance Sheets

(in thousands)

| | January 31, 2010 (Unaudited) | April 30, 2009 |
|---|------------------------------------|-------------------|
| <u>Assets</u> | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 1,937 | \$ 3,559 |
| Restricted cash | 506 | 456 |
| Receivables, less allowance | 23,007 | 24,526 |
| Inventories | 7,924 | 7,839 |
| Deferred income taxes | 330 | 309 |
| Prepaid expenses and other current assets | 1,255 | 856 |
| Total current assets | 34,959 | 37,545 |
| Property, plant and equipment, at cost | 41,738 | 39,298 |
| Accumulated depreciation | (29,129) | (27,929) |
| Net property, plant and equipment | 12,609 | 11,369 |
| Deferred income taxes | 351 | 351 |
| Other | 3,684 | 3,264 |
| Total other assets | 4,035 | 3,615 |
| Total Assets | \$ 51,603 | \$ 52,529 |
| <u>Liabilities and Stockholders' Equity</u> | | |
| Current liabilities: | | |
| Short-term borrowings | \$ 2,909 | \$ 5,720 |
| Current obligations under capital leases | 96 | 220 |
| Accounts payable | 6,082 | 8,812 |
| Employee compensation and amounts withheld | 1,521 | 1,709 |
| Deferred revenue | 708 | 1,298 |
| Other accrued expenses | 2,316 | 904 |
| Total current liabilities | 13,632 | 18,663 |
| Obligations under capital leases | 139 | 201 |
| Accrued employee benefit plan costs | 6,533 | 5,406 |
| Total Liabilities | 20,304 | 24,270 |
| Equity: | | |
| Common Stock | 6,550 | 6,550 |
| Additional paid-in-capital | 765 | 614 |
| Retained earnings | 28,127 | 25,802 |
| Accumulated other comprehensive loss | (5,298) | (5,521) |
| Common stock in treasury, at cost | (470) | (492) |
| Total Kewaunee Scientific Corporation stockholders' equity | 29,674 | 26,953 |
| Noncontrolling interest | 1,625 | 1,306 |

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

| | | |
|--|-----------|-----------|
| Total Equity | 31,299 | 28,259 |
| Total Liabilities and Stockholders' Equity | \$ 51,603 | \$ 52,529 |

See accompanying notes to consolidated financial statements.

Table of Contents*Kewaunee Scientific Corporation*

Consolidated Statements of Cash Flows

*(Unaudited)**(in thousands)*

| | Nine months ended January 31 | |
|---|---|-----------------|
| | 2010 | 2009 |
| <i>Cash flows from operating activities:</i> | | |
| Net earnings | \$ 3,044 | \$ 3,327 |
| Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | | |
| Depreciation | 1,840 | 1,687 |
| Bad debt provision | 107 | 164 |
| Provision for deferred income tax expense | (21) | (10) |
| Decrease in prepaid income taxes | 9 | 812 |
| Decrease (increase) in receivables | 1,412 | (4,800) |
| Increase in inventories | (85) | (694) |
| Increase in prepaid pension cost | | (222) |
| (Decrease) increase in accounts payable and other accrued expenses | (1,506) | 265 |
| (Decrease) increase in deferred revenue | (590) | 364 |
| Other, net | 817 | (553) |
| Net cash provided by operating activities | 5,027 | 340 |
| <i>Cash flows from investing activities:</i> | | |
| Capital expenditures | (3,080) | (1,156) |
| (Increase) decrease in restricted cash | (50) | 82 |
| Net cash used in investing activities | (3,130) | (1,074) |
| <i>Cash flows from financing activities:</i> | | |
| (Decrease) increase in short-term borrowings | (2,811) | 1,264 |
| Payments on capital leases | (186) | (280) |
| Dividends paid | (719) | (613) |
| Dividends paid to minority interest in subsidiaries | | (498) |
| Purchase of treasury stock | (245) | (198) |
| Proceeds from exercise of stock options (including tax benefit) | 267 | 298 |
| Net cash used in financing activities | (3,694) | (27) |
| Effect of exchange rate changes on cash | 175 | (332) |
| <i>Decrease in cash and cash equivalents</i> | (1,622) | (1,093) |
| <i>Cash and cash equivalents, beginning of period</i> | 3,559 | 3,784 |
| <i>Cash and cash equivalents, end of period</i> | \$ 1,937 | \$ 2,691 |

See accompanying notes to consolidated financial statements

Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's 2009 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. In preparing these interim consolidated financial statements, we have reviewed and considered for disclosure all significant events occurring through March 12, 2010, the date of financial statement issuance.

B. Inventories

Inventories consisted of the following (in thousands):

| | January 31, 2010 | April 30, 2009 |
|-------------------|------------------|----------------|
| Finished products | \$ 1,871 | \$ 1,756 |
| Work in process | 1,521 | 1,461 |
| Raw materials | 4,532 | 4,622 |
| | \$ 7,924 | \$ 7,839 |

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

C. Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three and nine months ended January 31, 2010 and 2009 is as follows (in thousands):

| | Three months ended January 31, 2010 | Three months ended January 31, 2009 |
|---|--|--|
| Net earnings | \$ 621 | \$ 882 |
| Change in cumulative foreign currency translation adjustments | 39 | 82 |
| Change in fair value of cash flow hedge, net of tax | (29) | |
| Total comprehensive income | \$ 631 | \$ 964 |

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

| | Nine months ended January 31, 2010 | Nine months ended January 31, 2009 |
|---|--|--|
| Net earnings | \$ 3,044 | \$ 3,327 |
| Change in cumulative foreign currency translation adjustments | 252 | (642) |
| Change in fair value of cash flow hedge, net of tax | (29) | |
| Total comprehensive income | \$ 3,267 | \$ 2,685 |

Assets and liabilities for the Company's foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in stockholders' equity.

Table of Contents**D. Segment Information**

The following table provides financial information by business segments for the three and nine months ended January 31, 2010 and 2009 (in thousands):

| | Domestic Operations | International Operations | Corporate | Total |
|---|------------------------|-----------------------------|-----------|-----------|
| Three months ended January 31, 2010 | | | | |
| Revenues from external customers | \$ 19,081 | \$ 2,733 | \$ | \$ 21,814 |
| Intersegment revenues | 477 | 23 | (500) | |
| Operating earnings (loss) before income taxes | 1,538 | 127 | (678) | 987 |
| Three months ended January 31, 2009 | | | | |
| Revenues from external customers | \$ 22,498 | \$ 3,525 | | \$ 26,023 |
| Intersegment revenues | 347 | 234 | (581) | |
| Operating earnings (loss) before income taxes | 1,769 | 302 | (623) | 1,448 |
| Nine months ended January 31, 2010 | | | | |
| Revenues from external customers | \$ 67,152 | \$ 7,999 | \$ | \$ 75,151 |
| Intersegment revenues | 1,169 | 441 | (1,610) | |
| Operating earnings (loss) before income taxes | 6,984 | 636 | (2,681) | 4,939 |
| Nine months ended January 31, 2009 | | | | |
| Revenues from external customers | \$ 67,296 | \$ 11,854 | \$ | \$ 79,150 |
| Intersegment revenues | 1,984 | 259 | (2,243) | |
| Operating earnings (loss) before income taxes | 6,501 | 1,025 | (2,373) | 5,153 |

E. Defined Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. No contributions were paid to the plans during the nine months ended January 31, 2010, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year.

Pension expense (income) consisted of the following (in thousands):

| | Three months ended January 31, 2010 | Three months ended January 31, 2009 |
|--|---|--|
| Service Cost | \$ -0- | \$ -0- |
| Interest Cost | 238 | 224 |
| Expected return on plan assets | (235) | (338) |
| Recognition of net loss | 174 | 40 |
| Net periodic pension expense (income) | \$ 177 | \$ (74) |

| | Nine months ended January 31, 2010 | Nine months ended January 31, 2009 |
|--------------------------------|---|--|
| Service Cost | \$ -0- | \$ -0- |
| Interest Cost | 713 | 672 |
| Expected return on plan assets | (704) | (1,014) |
| Recognition of net loss | 521 | 120 |

| | | | | |
|---------------------------------------|----|-----|----|-------|
| Net periodic pension expense (income) | \$ | 530 | \$ | (222) |
|---------------------------------------|----|-----|----|-------|

Table of Contents

F. Credit Arrangement

In July 2009, the Company amended its unsecured revolving credit facility to extend the facility's expiration date to July 31, 2012, and modify the variable rate component of the interest calculation. Monthly interest payments under the facility, as amended, are payable calculated at the 30-day LIBOR Market Interest Rate plus a variable rate ranging from 1.575% to 2.175%.

G. Derivative Instruments and Hedging Activities

Cash Flow Hedges Interest Rate Swap Agreement

In July 2009, the Company entered into an interest rate SWAP agreement whereby the interest rate payable by the Company on \$2 million of outstanding advances under the revolving credit facility was effectively converted to a fixed interest rate of 3.9% for the period beginning August 3, 2009, and ending August 1, 2012.

The Company entered into this interest rate swap to mitigate future interest rate risk associated with advances under the credit facility. The Company does not use derivatives for trading or speculative purposes. The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (loss) and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Company did not record any hedge ineffectiveness in earnings during the three months or nine months ended January 31, 2010 and 2009. Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to interest expense as interest payments are made on the Company's revolving credit facility.

The change in fair value of cash flow hedge, net of tax for the three and nine months ended January 31, 2010 was \$29,000. The change in fair value was recorded in the Company's consolidated balance sheet as a current liability and accumulated other comprehensive loss.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The Company's 2009 Annual Report to Stockholders contains management's discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2009. The following discussion and analysis describes material changes in the Company's financial condition since April 30, 2009. The analysis of results of operations compares the three and nine months ended January 31, 2010 with the comparable periods of the prior fiscal year.

Results of Operations

Sales for the three months ended January 31, 2010 were \$21,814,000, a decrease of 16% from sales of \$26,023,000 in the same period last year. Sales from Domestic Operations were \$19,081,000, a decrease of 15% from the prior year period. Sales from Domestic Operations for the three month period were affected by a soft market for small laboratory furniture projects, and unusually bad weather which delayed the start of many construction projects. Sales from International Operations were \$2,733,000, a decrease of 22% from the prior year period.

Sales for the nine months ended January 31, 2010 were \$75,151,000, a decrease of 5% from sales of \$79,150,000 in the same period last year. Sales from Domestic Operations were \$67,152,000, relatively unchanged when compared to the prior year period. Sales from International Operations were \$7,999,000, a decrease of 33% from the prior year period. The decline in International Operations sales for both the three and nine month periods resulted from lower demand resulting from the slowdown in Asia of construction activity. The order backlog at January 31, 2010 was \$65.5 million, as compared to a backlog of \$65.2 million at October 31, 2009 and \$60.7 million at January 31, 2009.

The gross profit margin for the three months ended January 31, 2010 was 21.5% of sales, as compared to 19.0% of sales in the comparable quarter of the prior year. The gross profit margin for the nine months ended January 31, 2010 was 22.2% of sales, as compared to 20.6% of sales in the comparable quarter of the prior year. The increases in the gross profit margin percentages were primarily due to increased manufacturing efficiencies, savings from alternative sources of raw materials and components, and other cost improvements.

Operating expenses for the three months ended January 31, 2010 were \$3,663,000, or 16.8% of sales, as compared to \$3,440,000, or 13.2% of sales, in the comparable period of the prior year. Operating expenses for the nine months ended January 31, 2010 were \$11,605,000, or 15.4% of sales, as compared to \$10,884,000, or 13.8% of sales, in the comparable period of the prior year. The increase in operating expenses for the current quarter was primarily due to an increase of \$295,000 for costs associated with benefit plans, \$208,000 for sales and marketing costs, and

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

an increase of \$32,000 in depreciation expense, partially offset by lower expenses of \$205,000 related to accrued compensation for incentive bonus plans. The increase in operating expenses for the nine months of the current year was primarily due to an increase of \$234,000 in administrative salaries, an increase of \$753,000 for costs associated with benefit plans, and an increase of \$98,000 in depreciation expense, partially offset by lower expenses of \$392,000 related to accrued compensation for incentive bonus plans.

Table of Contents

Operating earnings were \$1,022,000 and \$5,054,000 for the three and nine months ended January 31, 2010. This compares to operating earnings of \$1,494,000 and \$5,420,000 for the comparable periods of the prior year.

Interest expense was \$35,000 and \$115,000 for the three and nine months ended January 31, 2010, respectively, as compared to \$49,000 and \$231,000 for the comparable periods of the prior year. The decrease in interest expense for the current year periods resulted from lower interest rates paid on advances under the Company's bank credit facility.

There was no other income and other expense in the three and nine months ended January 31, 2010, as compared to other income of \$3,000 and other expense of \$36,000 for the three and nine months ended January 31, 2009, respectively.

Income tax expense of \$333,000 and \$1,673,000 was recorded for the three and nine months ended January 31, 2010, respectively, as compared to income tax expense of \$488,000 and \$1,595,000 recorded for the comparable periods of the prior year. The effective tax rates were 33.7% and 33.9% for the three and nine months ended January 31, 2010, respectively, and were 33.7% and 31.0% for the comparable periods of the prior year. The effective tax rates for each of the current year and prior year periods were below the statutory tax rates due to the combination of lower income tax rates in the geographic locations of the Company's subsidiaries and the impact of state and federal income tax credits on domestic operations income. The higher effective tax rates for the current year period as compared to the prior year period was due to a higher portion of taxable earnings in the prior year period from the Company's subsidiaries located in geographic locations with lower income tax rates.

Minority interests related to the Company's two subsidiaries that are not 100% owned by the Company reduced net earnings by \$33,000 and \$222,000 for the three and nine months ended January 31, 2010, as compared to a reduction of \$78,000 and \$231,000 for the comparable periods of the prior year. The decrease in minority interests in the current year periods was directly related to lower earnings of the Company's two subsidiaries in the current year.

Net earnings were \$621,000, or \$0.24 per diluted share, and \$3,044,000, or \$1.18 per diluted share, for the three and nine months ended January 31, 2010. This compares to net earnings of \$882,000, or \$0.35 per diluted share, and \$3,327,000, or \$1.30 per diluted share, for the comparable periods of the prior year.

Liquidity and Capital Resources

Historically, the Company's principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company's revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of \$21.3 million at January 31, 2010, compared to \$18.9 million at April 30, 2009. The ratio of current assets to current liabilities was 2.6-to-1.0 at January 31, 2010, compared to 2.0-to-1.0 at April 30, 2009. At January 31, 2010, advances of \$2,909,000 were outstanding under the Company's bank revolving credit facility, as compared to advances of \$5,720,000 outstanding as of April 30, 2009.

The Company's operations provided cash of \$5,027,000 during the nine months ended January 31, 2010. Cash was provided primarily from operating earnings and a decrease of \$1,412,000 in accounts receivable. The Company's operations provided cash of \$340,000 during the nine months ended January 31, 2009 as cash provided from operating earnings was substantially offset by cash used to fund an increase of \$4,800,000 in accounts receivable.

During the nine months ended January 31, 2010, net cash of \$3,130,000 was used in investing activities, primarily for capital expenditures. This compares to the use of \$1,074,000 for investing activities in the comparable period of the prior year, primarily for capital expenditures.

The Company's financing activities used cash of \$3,694,000 during the nine months ended January 31, 2010. Cash used included cash dividends of \$719,000 paid to stockholders, payments on obligations of capital leases of \$186,000, purchases of treasury stock of \$245,000, and \$2,811,000 for a reduction in short-term borrowings, partially offset by \$267,000 in proceeds received from the exercise of stock options. The Company's financing activities used cash of \$27,000 during the nine months ended January 31, 2009. Cash used included cash dividends of \$498,000 paid to minority interest holders of the Company's subsidiaries, cash dividends of \$613,000 paid to stockholders, payments on obligations of capital leases of \$280,000, and purchases of treasury stock of \$198,000. Cash was provided during this period by an increase of \$1,264,000 in short-term borrowings and \$298,000 in proceeds received from the exercise of stock options.

Table of Contents

Outlook for Fourth Quarter of Fiscal Year 2010

While the Company's ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company's role as subcontractor or supplier to dealers for subcontractors, the Company expects the fourth quarter of fiscal year 2010 to be profitable. In addition to general economic factors affecting the Company and its markets, demand for its products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes, belief, expects, plans, objectives, anticipates, intends or the like to be uncertain and forward-looking. Over time, the Company's results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company's forward-looking statements, and such difference might be significant and harmful to stockholders' interests. Many important factors that could cause such a difference are described under the caption Risk Factors, in Item 1A of the Company's 2009 Annual Report on Form 10-K.

Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and nine month periods ended January 31, 2010 and January 31, 2009 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company's registered public accounting firm. Their report on the interim consolidated financial information follows.

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of January 31, 2010, and the related consolidated statements of operations for the three month and nine month periods ended January 31, 2010 and 2009 and the related consolidated statements of cash flows for the nine-month periods ended January 31, 2010 and 2009. These interim consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2009 and the related consolidated statements of operations, of stockholder's equity and of cash flows for the year then ended (not presented herein) and in our report dated July 10, 2009, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2009 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

/s/ Cherry, Bekaert & Holland, L.L.P.

Charlotte, North Carolina

March 12, 2010

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2009.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company's management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2010. Based on that evaluation, the Company's management, including the CEO and CFO, concluded that, as of January 31, 2010, the Company's disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company's internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 6. Exhibits

- 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)

Date: March 12, 2010

By /s/ D. Michael Parker
D. Michael Parker

(As duly authorized officer and Senior Vice President, Finance
and Chief Financial Officer)